Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eishi Baba

Showing results (111-120 of 189) with videos related to

Pageof 19
Sort By:
Medical Oncology (Northwood, London, England)|January 3, 2012
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)Toshikazu Moriwaki, Hideaki Bando, Atsuo Takashima, et al.
International Journal of Clinical Oncology|July 10, 2019
Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First EditionSaori Mishima, Hiroya Taniguchi, Kiwamu Akagi, et al.
International Journal of Clinical Oncology|October 21, 2020
Safety and efficacy of S-1 plus oxaliplatin 130 mg/m<sup>2</sup> combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A)Tomomi Kashiwada, Katsunori Shinozaki, Shohei Ueno, et al.
International Journal of Clinical Oncology|January 4, 2019
Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancerTomoyasu Yoshihiro, Hitoshi Kusaba, Akitaka Makiyama, et al.
Oncology Letters|January 2, 2016
Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case reportKyoko Inadomi, Hozumi Kumagai, Kotoe Takayoshi, et al.
Cancer Chemotherapy and Pharmacology|June 28, 2017
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancerKotoe Takayoshi, Hitoshi Kusaba, Masato Uenomachi, et al.
Medicine|April 12, 2018
Successful chemotherapeutic treatment for metastatic littoral cell angioma: A case reportKotoe Takayoshi, Goro Doi, Nobuhiro Tsuruta, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|December 20, 2011
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) studyAkira Sawaki, Yasuo Ohashi, Yasushi Omuro, et al.
Internal Medicine (Tokyo, Japan)|October 20, 2024
Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with PembrolizumabTakashi Matsumura, Kenji Tsuchihashi, Takeo Yamamoto, et al.
Molecular and Clinical Oncology|June 8, 2017
Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: A case reportTomoyasu Yoshihiro, Kenta Nio, Kenji Tsuchihashi, et al.
Pageof 19

Showing results (111-120 of 189) with videos related to

Sort By:
Pageof 19
Medical Oncology (Northwood, London, England)|January 3, 2012
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)Toshikazu Moriwaki, Hideaki Bando, Atsuo Takashima, et al.
International Journal of Clinical Oncology|July 10, 2019
Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First EditionSaori Mishima, Hiroya Taniguchi, Kiwamu Akagi, et al.
International Journal of Clinical Oncology|October 21, 2020
Safety and efficacy of S-1 plus oxaliplatin 130 mg/m<sup>2</sup> combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A)Tomomi Kashiwada, Katsunori Shinozaki, Shohei Ueno, et al.
International Journal of Clinical Oncology|January 4, 2019
Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancerTomoyasu Yoshihiro, Hitoshi Kusaba, Akitaka Makiyama, et al.
Oncology Letters|January 2, 2016
Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case reportKyoko Inadomi, Hozumi Kumagai, Kotoe Takayoshi, et al.
Cancer Chemotherapy and Pharmacology|June 28, 2017
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancerKotoe Takayoshi, Hitoshi Kusaba, Masato Uenomachi, et al.
Medicine|April 12, 2018
Successful chemotherapeutic treatment for metastatic littoral cell angioma: A case reportKotoe Takayoshi, Goro Doi, Nobuhiro Tsuruta, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|December 20, 2011
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) studyAkira Sawaki, Yasuo Ohashi, Yasushi Omuro, et al.
Internal Medicine (Tokyo, Japan)|October 20, 2024
Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with PembrolizumabTakashi Matsumura, Kenji Tsuchihashi, Takeo Yamamoto, et al.
Molecular and Clinical Oncology|June 8, 2017
Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: A case reportTomoyasu Yoshihiro, Kenta Nio, Kenji Tsuchihashi, et al.
Pageof 19